Late normal tissue injury from permanent interstitial implants

International Journal of Radiation Oncology Biology Physics

Volumn 49, Issue 4, 2001, Pages 1163-1169

  Yaes, R J ^a  

^a Radiopharmaceutical Drug Products   (United States)

Author keywords

103Pd; 125I; 198Au; Biologically effective dose; Hot spots; Prostate implants

Indexed keywords

GOLD 198; IODINE 125; PALLADIUM 103;

ARTICLE; DOSIMETRY; IMPLANT; MATHEMATICAL MODEL; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; RADIATION INJURY;

ALGORITHMS; BRACHYTHERAPY; GOLD RADIOISOTOPES; HALF-LIFE; HUMANS; IODINE RADIOISOTOPES; LINEAR MODELS; PALLADIUM; RADIOISOTOPES; RADIOTHERAPY DOSAGE; RELATIVE BIOLOGICAL EFFECTIVENESS;

EID: 0035869718     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(00)01425-5     Document Type: Article

References (23)

1. Tolerance of normal tissue to therapeutic irradiation
2. On using the linear-quadratic model in daily clinical practice
3. Dose fractionation, dose rate and isoeffect relationships for normal tissue responses
4. An incomplete repair model for survival after fractionated and continuous irradiation
5. The application of the linear-quadratic dose-effect equation to fractionated and protracted radiation
6. Expression of the dose rate effect in clinical curietherapy
7. Radiobiological assessment of permanent implants using tumor repopulation factors in the linear-quadratic model
8. Effect of tumor shrinkage on the biological effectiveness of permanent brachytherapy implants
9. Permanent implants using Au-198, Pd-103, and I-125; Radiobiological considerations
10. Application of the linear-quadratic model with incomplete repair to radionucleide therapy
11. Derivation and application of equations describing the effects of fractionated protracted irradiation, based on multiple and incomplete processes. Part 2 analysis of mouse lung data
12. A generalized formulation of the 'incomplete repair' model for cell survival and tissue response to fractionated low dose-rate radiation
13. Dose rate effect in biologically targeted radiotherapy
14. Comparison of the predictions of the LQ and CRE models for normal tissue damage due to biologically targeted radiotherapy with exponentially decaying dose rate
15. The radiobiology of targeted radiotherapy
16. The curability of tumors of differing size using 131I or 90Y
17. Palladium-103 brachytherapy for clinical T1/T2 prostate carcinomas
18. Dosimetry guidelines to minimize urethral and rectal morbidity following transperineal I-125 prostate brachytherapy
19. Comparison of the 5-year outcome and morbidity of three-dimensional conformal radiotherapy versus transperineal permanent iodine-125 implantation for early stage prostate cancer
20. Urinary morbidity following ultrasound guided transperineal prostate seed implantation
21. Long-term complications with prostate implants; Iodine-125 vs. palladium-103
22. The hazard of accelerated tumor clonogen repopulation during radiotherapy
23. The effect of overall treatment time on the outcome of definitive radiotherapy for localized prostate carcinoma; The Radiation Therapy Oncology Group 75-06 and 77-06 experience